In the pharmaceutical industry, Cinnarizine is a versatile molecule acting as both an Antihistamine and a Calcium Channel Blocker. As a pharmacist and manufacturer, I view its safety profile with caution, as it has a direct impact on the central nervous system and specific contraindications that must be strictly observed to avoid severe neurological complications.
At your WHO-GMP facility in Mumbai, where you likely produce the 25 mg and 75 mg (Stugeron) strengths, identifying who cannot take this drug is vital for your technical dossiers and B2B marketplace compliance.
Strict Contraindications (Who MUST NOT take it)
-
Parkinson’s Disease (Absolute Contraindication): Cinnarizine is a dopamine antagonist. It can significantly worsen tremors and rigidity in Parkinson’s patients and has been known to cause Drug-Induced Parkinsonism in healthy elderly patients after long-term use.
-
Porphyria: It is considered unsafe for patients with this rare genetic blood disorder, as it may trigger acute attacks.
-
Severe Liver or Kidney Disease: Since the drug is metabolized by the liver and excreted by the kidneys, patients with severe impairment are at high risk for “accumulation toxicity.”
-
Hypersensitivity: Anyone with a known allergy to cinnarizine or other piperazine derivatives.
High-Risk Groups (Precautions Required)
-
The Elderly: Older adults are more susceptible to the “extrapyramidal” side effects (unusual muscle movements) and confusion.
-
Pregnant & Breastfeeding Women: Safety has not been established. It is generally not recommended unless the clinical benefit clearly outweighs the fetal risk. It is also not recommended during lactation.
-
Children under 5 Years: Cinnarizine is typically not licensed for use in children below the age of 5.
-
Glaucoma & Urinary Retention: Due to its mild anticholinergic effects, it can increase eye pressure (Primary Angle Closure Glaucoma) and worsen symptoms of an enlarged prostate.
-
Epilepsy: It may lower the seizure threshold in some patients.
Critical Interactions: The “Do Not Mix” List
| Substance / Drug Class | Technical Interaction Effect |
| Alcohol | Severe Sedation: Alcohol significantly multiplies the drowsy effect of Cinnarizine. |
| CNS Depressants | (e.g., Diazepam, Zolpidem) Increases the risk of respiratory depression and extreme lethargy. |
| Tricyclic Antidepressants | (e.g., Amitriptyline) Enhances anticholinergic side effects like dry mouth and blurred vision. |
| Betahistine | Antagonism: These two drugs work against each other; taking them together reduces the efficacy of both for vertigo. |
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
The “Short-Term” USP: On your marketplace, emphasize that Cinnarizine is best used for acute episodes of vertigo (usually no more than 5 days) to avoid interfering with the brain’s natural “vestibular compensation” processes.
-
Stability for Export: Cinnarizine is light-sensitive. For export to Zone IVb tropical regions, utilizing Alu-Alu or Amber-colored PVDC blister packaging is essential to maintain a 36-month shelf life.
-
Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international tenders for Meniere’s disease and motion sickness.